Terns Pharmaceuticals Inc (TERN) Price

Arcellx Myeloma Data Pressures CAR-T Market

Arcellx and partner Kite (Gilead) announced strong Phase 2 data for their multiple myeloma CAR-T therapy, anito-cel, showing high response rates and durable efficacy. The results, presented at the ASH Annual Meeting, intensify competition in the crowded cell therapy market.